 |
Trial Information
Summary: Brain Imaging of Depression Using PET and AmphetamineThe purpose is to study brain chemisty of the brain chemical dopamine in depression in order to improve diagnosis and treatment of patients in the future. All participants will have a psychiatric and medical evaluation to determine eligibility. Eligible participants will have an MRI scan. This will be followed by two PET scans, one before and one after a single dose of the medical amphetamine. These scans are for research purposes and are of no direct benefit to participants. Participants are compensated $250 and offered three months of free treatment as needed. IRB # 4949 Patient Inclusion Criteria
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received. This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Trial listings updated: June 1, 2008 at 6:32:00 AM |
|
|
Patient Resources: [ Trial Listing
] [ Notification Services ] [ Drug
Directories ]
Copyright © 1995 - 2008, CenterWatch |
